Tim Eisen
Overview
Explore the profile of Tim Eisen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
5685
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ursprung S, Mossop H, Gallagher F, Sala E, Skells R, Sipple J, et al.
BMC Cancer
. 2021 Nov;
21(1):1238.
PMID: 34794412
Background: Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase...
12.
Halabi S, Yang Q, Carmack A, Zhang S, Foo W, Eisen T, et al.
Kidney Cancer J
. 2021 Nov;
19(3):64-72.
PMID: 34765076
Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets...
13.
Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, et al.
Contemp Clin Trials
. 2021 Sep;
108:106482.
PMID: 34538402
Background: 20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones...
14.
Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, et al.
Contemp Clin Trials
. 2021 Sep;
108:106481.
PMID: 34538401
The development of therapeutics in oncology is a highly active research area for the pharmaceutical and biotechnology industries, but also has a strong academic base. Many new agents have been...
15.
Armstrong A, Nixon A, Carmack A, Yang Q, Eisen T, Stadler W, et al.
Clin Cancer Res
. 2021 Jun;
27(12):3503.
PMID: 34117029
No abstract available.
16.
Armstrong A, Nixon A, Carmack A, Yang Q, Eisen T, Stadler W, et al.
Clin Cancer Res
. 2021 Feb;
27(12):3317-3328.
PMID: 33593885
Purpose: Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating...
17.
Eisen T, Frangou E, Oza B, Ritchie A, Smith B, Kaplan R, et al.
J Clin Oncol
. 2020 Oct;
38(34):4064-4075.
PMID: 33052759
Purpose: SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate or high risk of recurrence....
18.
Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, et al.
BMC Cancer
. 2020 Jul;
20(1):670.
PMID: 32680483
Background: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited. Thus, this study aimed...
19.
Aeppli S, Eboulet E, Eisen T, Escudier B, Fischer S, Larkin J, et al.
ESMO Open
. 2020 Jul;
5(Suppl 3).
PMID: 32669298
Background: The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection....
20.
Al-Lamki R, Hudson N, Bradley J, Warren A, Eisen T, Welsh S, et al.
Biology (Basel)
. 2020 Apr;
9(4).
PMID: 32272660
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully...